On October 2, 2025 Silicon Laboratories announced at its Works With Summit in Austin, Texas that the first products in its new Series 3 platform—SiMG301 and SiBG301—are now generally available. The announcement marked the first time the company’s silicon has been released for commercial production, with distribution partners worldwide authorized to ship the devices.
The Series 3 SoCs are built on an advanced 22 nm process and feature a multi‑core architecture that separates application, wireless, and security workloads. Each device offers up to 4 MB of Flash and 512 kB of RAM, and includes Silicon Labs’ PIXELRZ single‑wire interface for LED control. Crucially, the SiMG301 is the first silicon to achieve PSA Level 4 security, the highest certification level for protecting against laser fault injection, side‑channel analysis, micro‑probing, and voltage manipulation. The chip is also among the first to be included in the Connectivity Standards Alliance’s Matter Compliant Platform Certification program, enabling developers to ship Matter‑certified products faster with pre‑tested commissioning, networking, and message security.
The launch of Series 3 represents a significant strategic advance for Silicon Labs. By delivering generational gains in compute, connectivity, integration, and security, the new platform expands the company’s portfolio into more demanding, feature‑rich IoT designs while maintaining compatibility with its mature Series 2 ecosystem. The PSA Level 4 certification and Matter compliance position Silicon Labs as a leader in secure, interoperable edge devices, potentially accelerating adoption in connected healthcare, smart metering, and other high‑growth markets. This milestone is expected to strengthen the company’s competitive moat and open new revenue streams for the coming quarters.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.